Keynote lecture: Oral anticoagulation and DVT

Size: px
Start display at page:

Download "Keynote lecture: Oral anticoagulation and DVT"

Transcription

1 Keynote lecture: Oral anticoagulation and DVT What is the evidence? Is there a need to anticoagulate every lower leg DVT?

2 Disclosure Speaker name:...sebastian Schellong... I have the following potential conflicts of interest to report: X X Consulting (Boehringer, Bayer, BMS, Daiichi Sankyo, Aspen) Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other: speaker fees (Boehringer, Bayer, BMS, Daiichi Sankyo, Aspen) I do not have any potential conflict of interest 2

3 Therapy of VTE acute intermediate long term initial early maintenance long term maintenance Anticoagulation Thrombolysis Surgery Compression Therapy 3

4 Direct oral anticoagulants Drug Rivaroxaban(3) Apixaban(1;2) Edoxaban(5) Dabigatran(4) T max 2-4 h 3-4 h 1-2 h 0,5-2 h Bioavailability % (man) 49 % (man) 62 % (man) 6,5 % (man) Potential for drug-drug interactions CYP3A4/ P-GP-Inhibitors CYP3A4/ P-GP- Inhibitors P-GP- Inhibitors P-GP- Inhibitors Proteinbinding % 87 % 55 % 35 % t 1/ h ~12 h h h Renal clearance 33 % 27 % 50 % 80 % 4

5 Acute VTE studies with novel oral anticoagulants Hokusai-VTE EINSTEIN DVT EINSTEIN PE AMPLIFY RECOVER RECOVER 2 Drug Edoxaban Rivaroxaban Apixaban Dabigatran Study design Double-blind Open-label Double-blind Double-blind Heparin lead-in* At least 5 days None None At least 5 days Dosing schedule Edoxaban 60 mg qd (30 mg qd) Rivaroxaban 15 mg bid x 3 weeks followed by 20 mg qd Apixaban 10 mg bid x 7 days followed by 5 mg bid Dabigatran 150 mg bid NI margin Treatment duration Flexible 3 to 12 months Pre-specified 3, 6, or 12 months 6 months 6 months 5

6 Acute VTE studies with novel oral anticoagulants 6

7 Acute VTE studies with novel oral anticoagulants The HOKUSAI VTE Investigators: N Engl J Med 2013;369: ; EINSTEN-DVT: The EINSTEIN. Investigators NEJM 2010; 363: EINSTEIN-PE: The EINSTEIN-PE Investigators NEJM 2012; 366: ; AMPLIFY: Agnelli G et al. N Engl J Med 2013; 369: ; RE_COVER: Schulman S et al. New Engl J Med 2009; 361: ; RE- COVER2:Schulman S et al. Lancet 2013;

8 Metaanalysis 8

9 Metaanalysis 9

10 Metaanalysis 10

11 Approved treatment regimens of VTE Sequential therapy Traditional standard Sequential therapy NMH* s.c. VKA day 1 min. 3 months RE-COVER: Dabigatran Hokusai-VTE: Edoxaban NMH* s.c. Dabigatran 150mg b.i.d. / Edoxaban 60mg o.d. day 1 day 6-11 min. 3 months Monotherapy EINSTEIN-DVT/PE: Rivaroxaban Rivaroxaban 15mg b.i.d. for 3 weeks followed by 20 mg o.d. AMPLIFY: Apixaban *or UFH or Fondaparinux Apixaban 10mg b.i.d. for 1 week followed by 5 mg b.i.d. day 1 min. 3 months 11

12 Definition Small clot in the leg (ICVT) Distal Veins: Paired axial calf veins, calf muscle veins (soleal, gastrocnemial) Deep veins: axial calf veins as well as calf muscle veins Distal DVT: Isolated axial calf vein thrombosis Isolated calf muscle vein thrombosis Combined (Isolated calf vein thrombosis ICVT) Not included: Popliteal vein Trifurcation area (confluens region) 12

13 Ultrasound of distal veins Frequency Elias Schellong Stevens Subramaniam Bernardi Sevestre All DVT Prox/All Dist/All MVT/Dist 204 / % 275 / % 61 / % 113 / % 278 / % 1023 / % 112 / % 121 / % 42 / % 49 / % 213 / % 454 / % 92 / % 154 / % 19 / % 64 / % 65 / % 569 / % n.r. 76 / % DVT = deep vein thrombosis; prox = proximal; dist = distal; MVT = muscle vein thrombosis; n.r. = not reported n.r. n.r. n.r. n.r. 13

14 MASTERS registry Italy Palareti et al Thromb Haemost 2008; 99:

15 Natural history of VTE Pulmonary embolism Abortion Femoral / Iliac DVT Abortion Propagation Risk factor Propagation Risk factor Trifurcation / Popliteal DVT Propagation Abortion Risk factor Deep calf vein thrombosis Propagation Abortion Risk factor Muscle vein thrombosis 15

16 CALTHRO-study 3470 pts with suspected DVT 370 (10.7%) proximal DVT by CUS 431 Patienten No proximal DVT High clinical probability and/or positive D-Dimer Serial CUS after 5-7 days In parallel: blinded CCUS Blinded CCUS: 65 patients with ICVT Serial CUS: 2 proximal DVT (both with former ICVT) 3 mo FU: ICVT pos 1 prox DVT, 1 PE ICVT neg 1 prox DVT 0 PE Palareti G et al, Thromb Haemost

17 Natural history Galanaud et al, JTH

18 CACTUS trial Righini et al, Lancet Haematol

19 CACTUS trial NMH Placebo n=126 n=133 Sympt. Prox. DVT/PE (ITT) 3.3% 5.4% p=0.54 Sympt. Prox. DVT/PE (PP) 3.6% 5.6% p=0.55 ISTH major/crnm bleeding 4.1% 0.0% p=0.03 Righini et al, Lancet Haematol

20 Metaanalysis of Treatment for ICVT Franco et al, JTH 2017; 15:

21 Metaanalysis of Treatment for ICVT Anticoagulation vs no anticoagulation Recurrent VTE after 3 mo 0.50 [ ] NNT 20 Pulmonary Embolism 0.48 [ ] NNT 100 Any bleed 2.41 [ ] NNH 29 Major bleed 0.64 [ ] Anticoagulation > 6 weeks vs 6 weeks Recurrent VTE after 3 mo 0.39 [ ] Any bleed 2.07 [ ] Major bleed 3.25 [ ] Franco et al, JTH 2017; 15:

22 ACCP Guidelines 2016 ICVT ICVT provoked by surgery or by nonsurgical transient risk factor: Suggest anticoagulation 3 mo over shorter period Recommend anticoagulation 3 mo over longer timelimited period (eg. 6, 12, or24 mo) Recommend anticoagulation 3 mo over extended therapy (without a defined time limit) Remarks: Duration of treatment of patients with isolated distal DVT refers to patients in whom a decision has been made to treat with anticoagulation therapy; however, it is anticipated that not all patiens who are diagnosed with isolated distal DVT will be prescribed anticoagulants. 22

23 ACCP Guidelines 2016 ICVT Anticoagulation in case of D-Dimer is positive (particularly when markedly so without an alternative reason) thrombosis is extensive (eg. > 5 cm in length, involves multiple veins, > 7 mm in diameter) thrombosis is close to the proximal veins there is no reversible provoking factor for DVT active cancer history of VTE inpatient status 23

24 Discussion 24

Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.

Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study. Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research

More information

New areas of development for the direct oral anticoagulants

New areas of development for the direct oral anticoagulants New areas of development for the direct oral anticoagulants Varese March 2016 Disclosures for Harry R Büller Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory

More information

NOAC s across indications

NOAC s across indications Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich

More information

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular

More information

Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren

Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker

More information

The clinical relevance of AMPLIFY programme

The clinical relevance of AMPLIFY programme Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer

More information

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven

More information

Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT

Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN

More information

Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium

Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,

More information

DEEP VEIN THROMBOSIS (DVT): TREATMENT

DEEP VEIN THROMBOSIS (DVT): TREATMENT DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada

More information

Duration of anticoagulation

Duration of anticoagulation Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,

More information

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following

More information

Updates in venous thromboembolism. Cecilia Becattini University of Perugia

Updates in venous thromboembolism. Cecilia Becattini University of Perugia Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15

More information

Obesity, renal failure, HIT: which anticoagulant to use?

Obesity, renal failure, HIT: which anticoagulant to use? Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have

More information

The latest on the diagnosis and treatment of venous thromboembolism

The latest on the diagnosis and treatment of venous thromboembolism The latest on the diagnosis and treatment of venous thromboembolism Vicky Tagalakis MD FRCP Division of General Internal Medicine Jewish General Hospital McGill University Disclosures Advisory board Pfizer

More information

Status of anticoagulation therapy in 2016: Is there a need for venous revascularization?

Status of anticoagulation therapy in 2016: Is there a need for venous revascularization? Status of anticoagulation therapy in 2016: Is there a need for venous revascularization? Rupert M. Bauersachs Dept. of Vascular Medicine, Darmstadt Center of Thrombosis Hemostasis, Mainz Status of anticoagulation

More information

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine

More information

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)

More information

Anticoagulation: Novel Agents

Anticoagulation: Novel Agents Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical

More information

Rapid Fire-Top Articles You Need to Know

Rapid Fire-Top Articles You Need to Know Rapid Fire-Top Articles You Need to Know TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE

More information

New Oral Anticoagulant Drugs in the Prevention of DVT

New Oral Anticoagulant Drugs in the Prevention of DVT New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X

More information

Updates in Diagnosis & Management of VTE

Updates in Diagnosis & Management of VTE Updates in Diagnosis & Management of VTE Financial Disclosures-NONE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA,

More information

Anticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis

Anticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis Anticoagulation therapy following endovascular treatment of iliofemoral deep vein thrombosis Tim Sebastian, M.D. University Hospital Zurich Clinic for Angiology Disclosure Speaker name: Tim Sebastian I

More information

Direct oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens

Direct oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens Direct oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens Faculty disclosure Marie Antoinette Sevestre I disclose the following financial relationships: Paid

More information

Trombosi venose superficiali e trombosi venose distali

Trombosi venose superficiali e trombosi venose distali XXIV Congresso Nazionale SISET Abano 9-12 Novembre 2016 Trombosi venose superficiali e trombosi venose distali Gualtiero Palareti / Benilde Cosmi Università di Bologna Superficial vein thrombosis (SVT):

More information

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from

More information

With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis

With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April

More information

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM

More information

CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow

CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired

More information

Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging

Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical

More information

Expanding the treatment options of Superficial vein thrombosis with Rivaroxaban

Expanding the treatment options of Superficial vein thrombosis with Rivaroxaban Expanding the treatment options of Superficial vein thrombosis with Rivaroxaban Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health

More information

DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD

DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno

More information

The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for

The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,

More information

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma

More information

Acute and long-term treatment of VTE. Cecilia Becattini University of Perugia

Acute and long-term treatment of VTE. Cecilia Becattini University of Perugia Acute and long-term treatment of VTE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE The goals The acute PE phase After the acute phase Treatment for VTE Goals of acute treatment

More information

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew

More information

Cancer Associated Thrombosis An update.

Cancer Associated Thrombosis An update. Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID

More information

Venous Thromboembolic Disease Update

Venous Thromboembolic Disease Update Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada

More information

Acute and long-term treatment of PE. Cecilia Becattini University of Perugia

Acute and long-term treatment of PE. Cecilia Becattini University of Perugia Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One

More information

Anticoagulation Forum: Management of Tiny Clots

Anticoagulation Forum: Management of Tiny Clots Anticoagulation Forum: Management of Tiny Clots Casey O Connell, MD FACP Associate Professor Jane Anne Nohl Division of Hematology Keck School of Medicine USC DISCLOSURES None 4/11/2017 Objectives Define

More information

My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)?

My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)? My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)? November 24, 2018 Erica Peterson MD, FRCPC University of British Columbia Disclosures I participate in clinical research

More information

DOACs and CAT. 05 May 2017 NTW St Thomas Hospital

DOACs and CAT. 05 May 2017 NTW St Thomas Hospital DOACs and CAT Alexander (Ander) Cohen Vascular Medicine / Haematology Guy s and St Thomas Hospitals, King s College, London 05 May 2017 NTW St Thomas Hospital Disclosures for Dr. Alexander (Ander) T. Cohen

More information

Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach

Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach Prof. I. Baumgartner Head Clinical and Interventional Angiology About the ACCP guidelines Widely

More information

Management of Intermediate-Risk Pulmonary Embolism

Management of Intermediate-Risk Pulmonary Embolism Management of Intermediate-Risk Pulmonary Embolism Stavros V. Konstantinides, MD, PhD, FESC Professor, Clinical Trials in Antithrombotic Therapy Center for Thrombosis und Hemostasis, University of Mainz,

More information

Cancer Associated Thrombosis

Cancer Associated Thrombosis Cancer Associated Thrombosis Can we use DOACs? D R. C Y N T H I A W U MD F R C P ( C ) D I V I S I O N O F H E M A T O L O G Y F A M I L Y P H Y S I C I A N S A N D C A N C E R C O N T R O L A P R I L

More information

New Anticoagulants and Emerging Strategies

New Anticoagulants and Emerging Strategies New Anticoagulants and Emerging Strategies in the Treatment of Venous Thromboembolism b Stavros V. Konstantinides, MD, PhD, FESC Head, Department of Cardiology, Democritus University of Thrace, Greece

More information

Updates in Diagnosis & Management of VTE

Updates in Diagnosis & Management of VTE Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE

More information

New Anticoagulants Therapies

New Anticoagulants Therapies New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations

More information

Clinical issues which drug for which patient

Clinical issues which drug for which patient Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest

More information

New Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach. Dr. Johan Kurnianda, SpPD-KHOM

New Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach. Dr. Johan Kurnianda, SpPD-KHOM New Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach Dr. Johan Kurnianda, SpPD-KHOM VTE : Spectrum of Disease Deep Vein Thrombosis Post Thrombotic Syndrome Pulmonary

More information

Simplified approach to investigation of suspected VTE

Simplified approach to investigation of suspected VTE Simplified approach to investigation of suspected VTE Diagnosis of DVT and PE THSNA 2016, Chicago 15 April 2016 Clive Kearon, McMaster University, Canada Relevant Disclosures Research Support/P.I. Employee

More information

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin

More information

Non commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background

Non commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background Italian Journal of Medicine 2013; volume 7(s8):29-35 The treatment of venous thromboembolism with new oral anticoagulants Davide Imberti AUSL Piacenza, Italy ABSTRACT Traditional anticoagulants, such as

More information

I nuovi anticoagulanti orali nella trombosi venosa profonda. Terapia della TVP. Fulvio POMERO. Medicina Interna S. Croce e Carle Cuneo

I nuovi anticoagulanti orali nella trombosi venosa profonda. Terapia della TVP. Fulvio POMERO. Medicina Interna S. Croce e Carle Cuneo I nuovi anticoagulanti orali nella trombosi venosa profonda Terapia della TVP Fulvio POMERO Medicina Interna S. Croce e Carle Cuneo 1 2 3 Poor VKA control (first 90 days) Good VKA control (first 90 days)

More information

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin 1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,

More information

DOACs in SPECIAL POPULATIONS

DOACs in SPECIAL POPULATIONS DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy

More information

Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!)

Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!) Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!) Clinical Learning Day 2017 Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain

More information

Cancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School

Cancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School Cancer Associated Thrombosis: six months and beyond Farzana Haque Hull York Medical School Disclosure I have no disclosure The Challenge of Anticoagulation in Patients with Venous Thromboembolism and Cancer

More information

Blood Day for Primary Care

Blood Day for Primary Care Blood Day for Primary Care including the Anticoagulation, use of novel oral anticoagulants in DVT/PE & atrial fibrillation Marc Carrier MD MSc. FRCPC Department of Internal Medicine, Division of Hematology,

More information

Management of Cancer Associated VTE

Management of Cancer Associated VTE Management of Cancer Associated VTE Jean M. Connors, MD 2017 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine HMS

More information

DVT Diagnosis. Reference methods. Whole leg Ultrasonography. Predictive values. Page 1. Diagnosis of 1 st time symptomatic DVT.

DVT Diagnosis. Reference methods. Whole leg Ultrasonography. Predictive values. Page 1. Diagnosis of 1 st time symptomatic DVT. DVT Diagnosis Ulf Nyman Associate Professor Lund University Department of Radiology East Division (Kristianstad, HässleholmH Trelleborg, Ystad) Sweden Diagnosis of 1 st time symptomatic DVT Scientific

More information

ABSTRACT INTRODUCTION

ABSTRACT INTRODUCTION Adv Ther (2014) 31:473 493 DOI 10.1007/s12325-014-0119-7 REVIEW Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology

More information

Venous thrombosis in unusual sites

Venous thrombosis in unusual sites Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers

More information

New oral anticoagulants and Palliative Care.

New oral anticoagulants and Palliative Care. New oral anticoagulants and Palliative Care. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway

More information

Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON

Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON How to Prevent and Manage the Post-Thrombotic Syndrome? Jean-Philippe Galanaud Clinical Thromboembolism & Division of GIM Sunnybrook,

More information

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process

More information

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE

More information

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness

More information

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial Wednesday, June 6, 2018, 2:00PM ET Guest Author: David R. Anderson, MD Presenter: Sara Vazquez, PharmD Moderators:

More information

Mabel Labrada, MD Miami VA Medical Center

Mabel Labrada, MD Miami VA Medical Center Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and

More information

EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS

EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical

More information

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,

More information

Pulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy

Pulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy Pulmonary embolism: Acute management Cecilia Becattini University of Perugia, Italy Acute pulmonary embolism: Acute management Diagnosis Risk stratification Treatment Non-high risk PE: diagnosis 3-mo VTE

More information

New Developments in VTE Treatment

New Developments in VTE Treatment Disclosures: Accommodation at this meeting funded by Boehringer Investigator in phase III studies of Rivaroxiban, Dabigatran, Edoxaban New Developments in VTE Treatment GPCME meeting, August, Dunedin Dr

More information

C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School

C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School Novel Strategies to Prevent Pulmonary Embolism and DVT: APEX Trial and Substudies C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School Conflict of Interest Statement 2 Present Research/Grant

More information

Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017

Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017 Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in

More information

PULMONARY EMBOLISM/VTE CARE PROCESS MODEL

PULMONARY EMBOLISM/VTE CARE PROCESS MODEL PULMONARY EMBOLISM/VTE CARE PROCESS MODEL IMCP FALL CONFERENCE 2017 Scott Stevens, MD Co-Director, Thrombosis Clinic & Thrombosis Research Group Intermountain Medical Center Professor of Clinical Medicine

More information

USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY

USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY SDSHP ANNUAL MEETING CLINICAL PEARLS APRIL 7 TH, 2017 USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY STEFFANIE DANLEY, PHARM D, BCPS, CACP DISCLOSURE I have had no financial relationship over the past 12

More information

Chances and risks of direct oral anticoagulants for VTE

Chances and risks of direct oral anticoagulants for VTE LINC, Leipzig, 26.01.2016 Chances and risks of direct oral anticoagulants for VTE E. Lindhoff-Last Cardioangiologisches Centrum Bethanien (CCB) CCB Gefäß Centrum CCB Gerinnungs Centrum CCB Studien Centrum

More information

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144 Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144 Appendix A: Summary of new evidence from Summary of evidence from previous year Diagnosis Diagnostic

More information

New Strategies and New Data- Beyond Guidelines

New Strategies and New Data- Beyond Guidelines New Strategies and New Data- Beyond Guidelines Anthony Maraveyas GESCAT Lisbon 13 th October 2018 G.MA.GM.XA.12.2017.1962 Conflict of Interest Statement 2 u Research Support: Bayer, Boehringer Ingelheim,

More information

Updates in Management of Venous Thromboembolic Disease

Updates in Management of Venous Thromboembolic Disease Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures

More information

Duration of Therapy for Venous Thromboembolism

Duration of Therapy for Venous Thromboembolism Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee

More information

Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum

Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Online Data Supplement Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum Stacey M. Kassutto, C. Jessica Dine, Maryl Kreider, Rupal

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),

More information

IDEAL MANAGEMENT OF PULMONARY EMBOLISM DISCLOSURES

IDEAL MANAGEMENT OF PULMONARY EMBOLISM DISCLOSURES IDEAL MANAGEMENT OF PULMONARY EMBOLISM Samuel Z. Goldhaber, MD Section Head, Vascular Medicine Director, Thrombosis Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine

More information

Diagnosis and Management of Venous Thromboembolism

Diagnosis and Management of Venous Thromboembolism Diagnosis and Management of Venous Thromboembolism Muhammad Sajid Pervaiz Consultant Haematologist Chairman VTE committee Pennine Acute Hospitals NHS trust TOPICS 1-Introduction (Seriousness of problem)

More information

Disclosures. What is a Specialty Vein Clinic? Prevalence of Venous Disease. Management of Venous Disease: an evidence based approach.

Disclosures. What is a Specialty Vein Clinic? Prevalence of Venous Disease. Management of Venous Disease: an evidence based approach. Management of Venous Disease: an evidence based approach Disclosures Ed Boyle, MD Andrew Jones, MD Dr. Ed Boyle and Dr. Andrew Jones disclose Grants/research support: Medtronic, BTG International, Clearflow,

More information

Importance of VTE and Superficial Thrombosis for Primary and Emergency Care

Importance of VTE and Superficial Thrombosis for Primary and Emergency Care Importance of VTE and Superficial Thrombosis for Primary and Emergency Care Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner

More information

10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline

10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management

More information

Evidences for real-life use in fragile patients: Renal failure and cancer

Evidences for real-life use in fragile patients: Renal failure and cancer Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences

More information

A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention

A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention This handout is a supplemental resource to an educational video activity released on Medscape

More information

Kelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY

Kelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY Jedi Training 101: Mind-tricks & Evidence -Based Approaches to Combating Clinical Controversies in Anticoagulation Therapy Kelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY LEARNING

More information

Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust

Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust MANAGEMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) IN THE COMMUNITY SETTING & ANTICOAGULATION CLINICS THE PAST, PRESENT AND THE FUTURE Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital

More information

Clinical Cases with Deep Venous Thrombosis - The position of Apixaban Stavros KAKKOS, MD, MSc, PhD, RVT

Clinical Cases with Deep Venous Thrombosis - The position of Apixaban Stavros KAKKOS, MD, MSc, PhD, RVT Clinical Cases with Deep Venous Thrombosis - The position of Apixaban Stavros KAKKOS, MD, MSc, PhD, RVT Department of Vascular Surgery. University Hospital of Patras Chairman: Ioannis Tsolakis DISCLAIMER

More information

Edoxaban. Domenico Prisco Dipartimento di Medicina Sperimentale e Clinica Università di Firenze SOD Patologia Medica, AOU Careggi, Firenze

Edoxaban. Domenico Prisco Dipartimento di Medicina Sperimentale e Clinica Università di Firenze SOD Patologia Medica, AOU Careggi, Firenze Edoxaban Domenico Prisco Dipartimento di Medicina Sperimentale e Clinica Università di Firenze SOD Patologia Medica, AOU Careggi, Firenze Bologna 8 novembre 2013 Disclosures: DP has received research support

More information

Thromboembolism and cancer: New practices. Marc Carrier

Thromboembolism and cancer: New practices. Marc Carrier Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant

More information

Approach to Thrombosis

Approach to Thrombosis Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation

More information

Aspirin as Venous Thromboprophylaxis

Aspirin as Venous Thromboprophylaxis Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures

More information

New and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants

New and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives

More information